Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Exposure to higher levels of melatonin may be associated with lower breast cancer risk, but epidemiological evidence has been limited. We examined the relationship in a case-control study nested within the Diagnostisch Onderzoek Mammacarcinoom (DOM) study, and conducted a meta-analysis of prospective studies. METHODS: Concentrations of 6-sulfatoxymelatonin in pre-diagnostic first-morning urine voids were measured in 274 postmenopausal women diagnosed with breast cancer and 274 matched controls from the DOM study. Conditional logistic regression models were used to estimate multivariable-adjusted odds ratios (ORs) of breast cancer for thirds of 6-sulfatoxymelatonin. Meta-analysis of the current and previous prospective studies of urinary melatonin with breast cancer risk estimated the inverse-variance weighted averages of study-specific log-relative risks (RRs) of breast cancer for the highest versus lowest levels of 6-sulfatoxymelatonin. RESULTS: In the DOM study, the ORs of breast cancer for the middle and highest versus lowest thirds of 6-sulfatoxymelatonin were 0.70(95%CI:0.45-1.09) and 0.72(0.44-1.19), respectively. In the meta-analysis of the DOM study with six previous studies(2,296 cases), RR of breast cancer for the highest versus lowest levels of 6-sulfatoxymelatonin was 0.87(0.76-1.01). CONCLUSIONS: Results from the DOM study, together with the published prospective data, do not support a strong association of melatonin with breast cancer risk. IMPACT: This study adds to the relatively scarce prospective data on melatonin in relation to breast cancer risk. The totality of the prospective evidence does not clearly show an association between melatonin and breast cancer risk, but further data are needed to be able to exclude a modest association.

Original publication

DOI

10.1158/1055-9965.EPI-20-0822

Type

Journal article

Journal

Cancer Epidemiol Biomarkers Prev

Publication Date

03/11/2020